Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0946 • ACR Convergence 2021
Distinct Lipidomic Signatures in Synovium and Synovial Fluid of Patients with Rheumatoid Arthritis versus Psoriatic Arthritis
Beatriz Rocha¹, Berta Cillero-Pastor², Anna Illiano³, Valentina Calamia¹, Gabriella Pinto⁴, Angela Amoresano⁴, Cristina Ruiz-Romero⁵, Juan D Cañete⁶, Ron MA Heeren² and Francisco Blanco-García⁷, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006 A Coruña, España., A Coruña, Spain, ²The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands., Maastricht, Netherlands, ³CEINGE - Advanced Biotecnology, 80145 Napoli, Italy. Instituto Nazionale Biostrutture e Biosistemi (INBB), Rome, Italy., Naples, Italy, ⁴Department of Chemical Sciences, University of Naples “Federico II”, Napoli, Italy. Instituto Nazionale Biostrutture e Biosistemi (INBB), Rome, Italy, ⁵Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, ⁶Rheumatology Department, Hospital Clinic, Barcelona, Spain, ⁷Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain
Background/Purpose: The differential diagnosis of Rheumatoid Arthritis (RA) and Psoriatic arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of…
Abstract Number: 1321 • ACR Convergence 2021
Uveitis in Patients with Psoriatic Arthritis – a Database Analysis
Nizar Hijaze¹, Tal Gazitt², Amir Haddad³, Muna Elias⁴, Idit Lavi⁴, Ilan Feldhamer⁵, Arnon Dov Cohen⁵, Shaul Sar⁴, Oren Tomkins Netzr⁴ and Devy Zisman⁴, ¹Carmel medical centre, Tamra, Israel, ²Carmel Hospital, Haifa, Israel, ³Carmel Medical Centre, Haifa, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Clalit Health Services, Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) belongs to the group of spondyloarthropathies in which uveitis is an associated disease . The prevalence of uveitis among PsA patients…
Abstract Number: 1339 • ACR Convergence 2021
Treatment Persistence Was Similar at 3 Years in Patients with Psoriatic Arthritis Treated with Ustekinumab (STELARA®) or a Tumor Necrosis Factor Inhibitor in a Prospective Real-World Study
Laure Gossec¹, Stefan Siebert², Paul Bergmans³, Kurt de Vlam⁴, Elisa Gremese⁵, Beatriz Joven-Ibáñez⁶, Tatiana Korotaeva⁷, Wim Noël⁸, Michael Nurmohamed⁹, Petros Sfikakis¹⁰, Elke Theander¹¹ and Josef Smolen¹², ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²University of Glasgow, Glasgow, United Kingdom, ³Janssen-Cilag BV, Breda, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁶University Hospital 12 de Octubre, Madrid, Spain, ⁷VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁸Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁹Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ¹⁰National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹¹Janssen Cilag, Lund, Sweden, ¹²Medical University of Vienna, Vienna, Austria
Background/Purpose: Several options exist in the treatment of PsA, but data on long-term persistence are rare. Here, we assess long-term persistence with ustekinumab (UST) or…
Abstract Number: 1356 • ACR Convergence 2021
Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis in Psoriatic Arthritis
Ashley Elliott¹, Gary Wright², Adrian Pendleton² and Madeleine Rooney¹, ¹Centre for Experimental Medicine , School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, UK, Belfast, Northern Ireland, United Kingdom, ²Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom
Background/Purpose: Enthesitis is an important aspect of disease in PsA and its clinical assessment has problems in terms of sensitivity and overlap with alternative co-morbid…
Abstract Number: 1773 • ACR Convergence 2021
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials
Joris Diels¹, Pushpike Thilakarathne², Agata Schubert³, Fareen Hassan⁴, Steven Peterson⁵ and Wim Noël¹, ¹Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ²JanssenCilag Ltd, HEMAR Department, Beerse, Belgium, ³Janssen-Cilag Poland, HEMAR Department, Warsaw, Poland, ⁴Janssen-Cilag Ltd, HEMAR Department, High Wycombe, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ
Background/Purpose: Guselkumab is an anti-interleukin (IL)-23 monoclonal antibody recently approved for the treatment of psoriatic arthritis (PsA). In two large Phase III trials of patients…
Abstract Number: 1791 • ACR Convergence 2021
Psoriasis Onset Before Rheumatic Symptoms in Patients with Spondyloarthritis: Does It Relate to Clinical Characteristics and the Rheumatologist’s Diagnosis? Data from REGISPONSER Registry
Ignacio Gomez-Garcia¹, Teresa García-Puga², Nuria Barbarroja³, Mara ngeles Puche Larrubia⁴, Pilar Font⁵ and Clementina López Medina⁶, ¹Rheumatology Department, Reina Sofia University Hospital. Cordoba (Spain) / University of Cordoba (Spain) / Maimonides Institute for Biomedical Research (IMIBIC). Cordoba (Spain) / Physical Medicine and Rehabilitation Department. Infanta Margarita Hospital. Cabra (Spain), Córdoba, Spain, ²University of Cordoba, Cordoba, Spain, ³University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁴Hospital Universitario Reina Sofía, Córdoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France
Background/Purpose: To describe if the time of the onset of psoriasis (Pso) relative to the appearance of rheumatic symptoms in patients with spondyloarhtritis (SpA) is…
Abstract Number: 1808 • ACR Convergence 2021
Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial
Ana-Maria Orbai¹, Laura Coates², Atul Deodhar³, Philip S Helliwell⁴, Christopher Ritchlin⁵, Alexa Kollmeier⁶, Elizabeth Hsia⁷, Xie Xu⁷, Shihong Sheng⁷, Yusang Jiang⁷, Yan Liu⁷ and Chenglong Han⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁶Janssen Research & Development, LLC, La Jolla, CA, ⁷Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: In the DISCOVER-1 study, the anti-interleukin-23p19-subunit monoclonal antibody guselkumab (GUS) demonstrated robust efficacy across joint and skin clinical manifestations of psoriatic arthritis (PsA).1 Patients…
Abstract Number: 1826 • ACR Convergence 2021
Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis
William Tillett¹, Laura Coates², Sandeep Kiri³, Vanessa Taieb³ and Philip Mease⁴, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³UCB Pharma, Slough, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is associated with a reduction in workplace productivity,1 which may extend into household productivity.2 Certolizumab pegol (CZP) is a tumor necrosis…
Abstract Number: L03 • ACR Convergence 2020
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Jonghyeon Kim⁶, Shalabh Singhal⁶, Miroslawa Nowak⁶ and Subhashis Banerjee⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Leiden University Medical Center, Leiden, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signaling by key cytokines involved in psoriatic arthritis (PsA) pathophysiology. Deucravacitinib (BMS-986165) is a…
Abstract Number: 0169 • ACR Convergence 2020
Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
Juliette Yedimenko¹, Jessica Walsh², Alexis Ogdie³, Yuxuan Jin¹, Soumya Reddy⁴, Jose Scher⁵ and M. Elaine Husni¹, ¹Cleveland Clinic, Cleveland, OH, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, New York City
Background/Purpose: For psoriatic arthritis (PsA), several different composite instruments are available to define low disease activity (LDA) and remission (REM) targets for treatment. Patient-reported outcomes…
Abstract Number: 0318 • ACR Convergence 2020
Oxylipin Profile Is Associated with Skin Disease and Enthesitis in Psoriatic Disease
Roxana Coras¹, Arthur Kavanaugh², Angela Kluzniak³, Dustina Holt³, Amy Weilgosz³, Oswald Quehenberger¹, Christopher Ritchlin⁴ and Monica Guma⁵, ¹University of California San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ³University of Rochester Medical Center, New York, NY, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁵Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA), a systemic inflammatory disease, occurs in about 25% of patients with psoriasis (PsO). At present, there are no biomarkers that reliably…
Abstract Number: 0334 • ACR Convergence 2020
Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis
Philip Mease¹, Iain McInnes², Kiefer Eaton³, Steven Peterson⁴, Tim Disher⁵, Soumya Chakravarty⁶, Chetan Karyekar⁷, Sandhya Nair⁸, Wolf-Henning Boehncke⁹ and Christopher Ritchlin¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³EVERSANA, Burlington, Canada, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵EVERSANA, Sydney, Australia, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Global Services, LLC, Horsham, PA, ⁸Janssen Pharmaceutica NV, Beerse, ⁹Geneva University Hospitals, Geneva, Switzerland, ¹⁰Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: The efficacy of the interleukin (IL)-23 subunit p19 inhibitor guselkumab (GUS) for psoriatic arthritis (PsA) has recently been demonstrated in two Phase 3 trials…
Abstract Number: 0355 • ACR Convergence 2020
Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial
Georg Schett¹, Matthew J. Loza², Arumugam Palanichamy², Oliver FitzGerald³, Christopher Ritchlin⁴, Frédéric Baribaud⁵ and Kristen Sweet⁵, ¹Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ²Janssen Research & Development, LLC, Spring House, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Guselkumab (GUS), an interleukin-23p19-subunit monoclonal antibody, demonstrated efficacy compared to placebo (PBO) in reducing skin and musculoskeletal signs and symptoms in patients with active…
Abstract Number: 0381 • ACR Convergence 2020
Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis
Ana-Maria Orbai¹, Philip Mease², Philip Helliwell³, Oliver FitzGerald⁴, Mohamed Bedaiwi⁵, Dona Fleishaker⁶, Rajiv Mundayat⁶ and Pamela Young⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁵Division of Rheumatology, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Dactylitis, a hallmark of psoriatic arthritis (PsA), is a uniformly diffuse and sometimes painful swelling of the fingers and/or toes.1 Up to 50% of…
Abstract Number: 0873 • ACR Convergence 2020
Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Robert McLean², Taylor Blachley², Laura Anatale-Tardiff³, Christopher Saffore⁴, Charlie Lovan⁵ and Alexis Ogdie⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., North Chicago, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: When deciding to start patients with PsA on biologic therapy, rheumatologists may focus on skin involvement in addition to joint symptoms. The purpose of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].